SCHEMBL26650753

SCHEMBL26650753

CCCCCSCSCCCCCCCCC(=O)OC

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 2/20 0.49
POLA1 P09884 1/20 0.49
DGKA P23743 1/20 0.48
TSHR P16473 1/20 0.48
MAPT P10636 2/20 0.47
CES2 O00748 1/20 0.47
GMNN O75496 1/20 0.47
TP53 P04637 1/20 0.47
THRB P10828 1/20 0.47
CYP2C9 P11712 1/20 0.47
BLM P54132 1/20 0.47
HSD17B10 Q99714 1/20 0.47
CA12 O43570 1/20 0.46
CA2 P00918 1/20 0.46
CA7 P43166 1/20 0.46
CA9 Q16790 1/20 0.46
CA14 Q9ULX7 1/20 0.46
LMNA P02545 3/20 0.46
EPHX2 P34913 1/20 0.45
ALOX5 P09917 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26650816 1.00 POLB (0.49) POLBPOLA1DGKATSHRMAPT
SCHEMBL26650847 1.00 POLB (0.49) POLBPOLA1DGKATSHRMAPT
SCHEMBL15593806 0.93 TSHR (0.52) POLBPOLA1DGKATSHRMAPT
SCHEMBL29365230 0.93 TSHR (0.52) POLBPOLA1DGKATSHRMAPT
SCHEMBL9402917 0.89 TSHR (0.52) POLBPOLA1DGKATSHRMAPT
SCHEMBL26650784 0.87 TSHR (0.50) POLBPOLA1DGKATSHRMAPT
SCHEMBL11639760 0.85 CES2 (0.50) POLBPOLA1DGKATSHRMAPT
SCHEMBL10503461 0.85 CES2 (0.50) POLBPOLA1DGKATSHRMAPT
SCHEMBL11639935 0.85 CES2 (0.50) POLBPOLA1DGKATSHRMAPT
SCHEMBL8895243 0.85 CES2 (0.50) POLBPOLA1DGKATSHRMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260115139-A1 Amino Acid-Containing Ionizable Lipids for the Delivery of Therapeutic Agents NANOVATION THERAPEUTICS INC. (CA) 2026-04-30 US disclosed
US-20250304547-A1 Sulfur-Containing Lipids NANOVATION THERAPEUTICS INC. (CA) 2025-10-02 US disclosed
EP-4594293-A1 AMINO ACID-CONTAINING IONIZABLE LIPIDS FOR THE DELIVERY OF THERAPEUTIC AGENTS Nanovation Therapeutics Inc. (CA) 2025-08-06 EP disclosed
US-20240287015-A1 Method for Producing an Ionizable Lipid NANOVATION THERAPEUTICS INC. (CA) 2024-08-29 US disclosed
WO-2024065043-A1 AMINO ACID-CONTAINING IONIZABLE LIPIDS FOR THE DELIVERY OF THERAPEUTIC AGENTS NANOVATION THERAPEUTICS INC. (CA) 2024-04-04 WO disclosed
WO-2023215989-A1 SULFUR-CONTAINING LIPIDS NANOVATION THERAPEUTICS INC. (CA) 2023-11-16 WO disclosed
WO-2023215989-A1 SULFUR-CONTAINING LIPIDS NANOVATION THERAPEUTICS INC. (CA) 2023-11-16 WO disclosed
WO-2022246555-A1 METHOD FOR PRODUCING AN IONIZABLE LIPID NANOVATION THERAPEUTICS INC. (CA) 2022-12-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260115139-A1 Amino Acid-Containing Ionizable Lipids for the Delivery of Therapeutic Agents SLC43A1, SLC7A1, SLC7A5 POLB 364/4885POLA1 267/4885DGKA 1248/4885
US-20240287015-A1 Method for Producing an Ionizable Lipid CEL, FASN, COASY POLB 2233/4885POLA1 1402/4885DGKA 334/4885
US-20250304547-A1 Sulfur-Containing Lipids FABP1, SLC10A1, MPST POLB 1586/4885POLA1 1137/4885DGKA 1184/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.